These biomarkers were selected based on biological relevance to renal cell carcinoma, previous reports of prognostic significance, and the target profile of cabozantinib including both cabozantinib receptor targets (VEGFR2, MET, and AXL) and their ligands (VEGF, HGF, and GAS6). This evidence concerns the gene HGF and renal cell carcinoma.